These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 20684887

  • 1. Short-term withdrawal from imiglucerase: what can we learn from it?
    Hollak CE.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):105-6. PubMed ID: 20684887
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Successful desensitization to imiglucerase of an adult patient diagnosed with type I Gaucher disease.
    Erdoğdu D, Gelincik A, Canbaz B, Colakoğlu B, Büyüköztürk S, Tanakol R.
    Int Arch Allergy Immunol; 2013 Jan 15; 160(2):215-7. PubMed ID: 23018845
    [Abstract] [Full Text] [Related]

  • 8. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
    Elstein D, Altarescu G, Maayan H, Phillips M, Abrahamov A, Hadas-Halpern I, Tiomkin M, Zimran A.
    Blood Cells Mol Dis; 2012 Jan 15; 48(1):45-50. PubMed ID: 22047948
    [Abstract] [Full Text] [Related]

  • 9. Early access experience with VPRIV(®): recommendations for 'core data' collection.
    Hughes DA, Al-Sayed M, Belmatoug N, Bodamer O, Böttcher T, Cappellini M, Cohen IJ, Eagleton T, Elstein D, Giraldo P, Jones S, Kaplinsky C, Lund A, Machaczka M, Mengel E, Pastores GM, Rosenbaum H, Sjo M, Tiling N, Tsaftaridis P, Zimran A, Weinreb N.
    Blood Cells Mol Dis; 2011 Aug 15; 47(2):140-2. PubMed ID: 21146428
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep 15; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 13. Reduction in imiglucerase dosage causes immediate rise of chitotriosidase activity in patients with Gaucher disease.
    Chien YH, Lee NC, Tsai FJ, Chao MC, Hwu WL.
    Mol Genet Metab; 2010 Sep 15; 101(1):90-1. PubMed ID: 20580583
    [No Abstract] [Full Text] [Related]

  • 14. Evolving features in type 3 Gaucher disease on long-term enzyme replacement therapy.
    Elstein D, Abrahamov A, Altarescu G, Zimran A.
    Blood Cells Mol Dis; 2013 Feb 15; 50(2):140. PubMed ID: 23085428
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Successful rapid desensitization to imiglucerase in an adult patient with Gaucher disease and documented IgE-mediated hypersensitivity.
    Tsilochristou O, Gkavogiannakis NA, Ioannidou EN, Makris M.
    J Allergy Clin Immunol Pract; 2015 Feb 15; 3(4):624-6. PubMed ID: 25609344
    [No Abstract] [Full Text] [Related]

  • 17. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM.
    Curr Opin Investig Drugs; 2010 Apr 15; 11(4):472-8. PubMed ID: 20336596
    [Abstract] [Full Text] [Related]

  • 18. Treatment patterns from 647 patients with Gaucher disease: An analysis from the Gaucher Outcome Survey.
    Deegan P, Fernandez-Sasso D, Giraldo P, Lau H, Panahloo Z, Zimran A.
    Blood Cells Mol Dis; 2018 Feb 15; 68():218-225. PubMed ID: 27829541
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of imiglucerase supply shortage on clinical and laboratory parameters in Norrbottnian patients with Gaucher disease type 3.
    Machaczka M, Kämpe Björkvall C, Wieremiejczyk J, Paucar Arce M, Myhr-Eriksson K, Klimkowska M, Hägglund H, Svenningsson P.
    Arch Immunol Ther Exp (Warsz); 2015 Feb 15; 63(1):65-71. PubMed ID: 25205209
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.